|
|
|
|
|
Highlights from the 2022 American Urological Association Annual Meeting (AUA) |
|
|
|
|
| Plenary |
| AUA Guidelines: Localized Prostate Cancer |
| James Eastham, MD |
| The 2022 Annual Meeting of the American Urological Association was host to an AUA Guidelines sessions focused on localized prostate cancer, presented by Dr. James Eastham. The guidelines were divided into multiple sections: Risk Assessment, Staging, Risk-Based Management, and Principles of Management. |
|
|
|
|
|
| Confederación Americana de Urología (CAU) Lecture: The Fine Borderline between High-risk, Locally-advanced and Oligometastatic Prostate Cancer |
| Rafael Sanchez-Salas, MD |
| Rafael Sanchez-Salas addressed the contemporary paradigms of high-risk, locally advanced and oligometastatic prostate cancer. Dr. Sanchez-Salas outlined the following goals for his talk: Understand the importance of heterogeneity in high risk and locally advanced prostate cancer. Apprehend the positive impact of molecular imaging on lesion localization and stratification in the prostate cancer pathway. Conventional imaging is currently being replaced by next-generation imaging with a clear impact on therapeutic decision making. Genomic markers can further contribute to clinical particularization. |
|
|
|
|
|
| Prostate Cancer: Detection & Screening III |
| Racial and Ethnic Disparities Magnified After U.S. Preventative Services Task Force Category D Recommendation for PSA Screening |
| Caleb Bercu, BA |
| Caleb Bercu discussing the impact of the U.S. Preventative Services Task Force (USPSTF) Category D recommendation for PSA screening on racial and ethnic disparities. The incidence of metastatic prostate cancer has increased since 2008, and shifts in the USPSTF PSA screening recommendations may impact incidence of metastatic prostate cancer at presentation in racial and ethnic groups differently. |
|
|
|
|
|
| Disparities Regarding Shared Decision-Making in Prostate Cancer Screening |
| Michael Basin, MD |
| Michael Basin discussing disparities regarding shared decision-making in prostate cancer screening. Urologic prostate cancer screening guidelines universally recommend shared decision-making regarding PSA testing. The objective of this study presented by Dr. Basin and colleagues was to examine socio-demographic differences in shared decision-making for prostate cancer screening in the United States. |
|
|
|
|
|
| PSA Screening on a Nationwide Level: Featuring the Contribution of Race and Life Expectancy in Decision Making |
| Nicholas James Corsi |
| Nicholas Corsi discussing the impact of race and life expectancy in decision making for PSA screening at the nationwide level. Indeed, the mortality benefit of PSA screening is centered on patient’s life expectancy. While African American men represent a high-risk group for prostate cancer, there's limited evidence regarding the relationship between life expectancy and PSA screening in African American men. |
|
|
|
|
|
|
|
|
|
|
| Comparison Between Targeted versus Targeted Plus Standard Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Patients: A Randomized Controlled Trial
|
| Francesco Porpiglia, MD
|
| Francesco Porpiglia discussed a randomized trial comparing targeted versus targeted plus standard biopsy for prostate cancer diagnosis in biopsy naïve patients. In biopsy naïve patients with suspected prostate cancer, the indication to perform multiparametric magnetic resonance imaging (mpMRI) guided target biopsy associated to or in place of standard biopsy is still discussed.
|
|
|
|
|
|
| Prostate Cancer: Localized: Surgical Therapy II |
| Robot-Assisted PSMA-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe - a Prospective Feasibility Study |
| Hilda De Barros, MD, MSC |
| Hilda de Barros presented preliminary data regarding the feasibility of robotic-assisted, Prostate-Specific Membrane Antigen (PSMA)-targeted radio-guided salvage surgery. The use of intraoperative PSMA-targeted radio guidance has been shown to be valuable for the detection of recurrent prostate cancer lesions during open salvage surgery. |
|
|
|
|
|
|
|
|
|
|
| Reliability of 68Ga-PSMA PET/CT in Assessing Real Nodal Burden in Men With cN1 Disease: Clinical Implications for Patient Counselling and Multi-Modal Treatments |
| Armando Stabile, MD |
| In a moderated poster presentation at the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, Armando Stabilie presented on the clinical implications of 68Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT to quantify nodal disease burden in patients with cN1 disease. |
|
|
|
|
|
| Prostate Cancer: Advanced (Including Drug Therapy) I |
| Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates For Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy
|
| Elio Mazzone, Ph.D.
|
| Elio Mazzone presented an analysis aimed at identifying subgroups of patients with adverse pathology at the time of radical prostatectomy who may benefit from adjuvant radiotherapy. While an adjuvant radiotherapy approach for patients with adverse pathological findings at the time of radical prostatectomy was guideline recommended for many years, it was infrequently utilized in part due to concerns for overtreatment and treatment-related toxicity.
|
|
|
|
|
|
| Comparison of Clinical Outcomes Between Androgen Deprivation Therapy with Up-Front Abiraterone and Bicalutamide for Japanese Patients with LATITUDE High-Risk Prostate Cancer in a Real-World Multicenter Analysis
|
| Taku Naiki, MD, Ph.D.
|
| Taku Naiki presented an analysis of abiraterone and bicalutamide (each with androgen deprivation therapy (ADT)) in metastatic castration-sensitive prostate cancer (mCSPC). These real world data demonstrated that the upfront use of abiraterone in addition to ADT is associated with improved oncologic outcomes compared to conventional combined androgen blockade with bicalutamide in patients with LATITUDE high-risk mCSPC.
|
|
|
|
|
|
| Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial
|
| Taro Iguchi, MD
|
| Taro Iguchi presented a post hoc analysis of the ARCHES trial assessing the effect of prior local therapy on the efficacy of enzalutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
| Prostate Cancer: Advanced (Including Drug Therapy) II |
| Quantitative Piflufolastat F18 PSMA Scan Indices as a Response Imaging-Biomarker to Androgen Deprivation Therapy in Veterans with Newly Diagnosed Metastatic Prostate Cancer |
| Nicholas Nickols, MD, Ph.D. |
Nicholas Nickols discussed quantitative piflufolastat F18 PSMA scan indices as a response imaging-biomarker to androgen deprivation therapy in veterans with newly diagnosed metastatic prostate cancer. In this study, Dr. Nickols and colleagues associated the quantitative changes in total PSMA tumor burden in lymph nodes and bone with that of PSA.
|
|
|
|
|
|
| Initial Experience of [177Lu] Ludotadipep Treatment in Patients with [18F]PSMA PET CT Positive mCRPC: Preliminary Study |
| Dongho Shin, MD |
| Dongho Shin discussed preliminary results of the initial experience of [177Lu] Ludotadipep treatment in patients with [18F] PSMA PET CT positive metastatic castration-resistant prostate cancer (mCRPC). The current study is in the early stages of [177Lu] Ludotadipep treatment, with a final target capacity of 150 mCi. [177Lu] Ludotadipep could be a promising treatment with less toxicity for mCRPC patients who have not been responsive to conventional treatments. |
|
|
|
|
|
| Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies |
| Neal D. Shore, MD, FACS |
| The 2022 American Urological Association (AUA) Annual Meeting included a session on advanced prostate cancer and a presentation by Neal Shore discussing oral relugolix for ADT in advanced prostate, specifically a pooled safety analysis from randomized trials. In the pooled analyses of 2 randomized clinical studies in advanced prostate cancer, relugolix was generally well tolerated, with a lesser incidence of major adverse cardiovascular events relative to leuprolide. |
|
|
|
|
|
|
